Krystal Biotech (KRYS) P/S ratio

P/S ratio today
23.0×

Krystal Biotech (KRYS) trades at 23.0× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 19.0×. That is 18.3% higher than the 16.0× of fiscal 2024. Figures as of 18 Nov 2026, 10:48 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
23.0×
P/S ratio, fiscal 2025
19.0×
Change on fiscal 2024
+18.3%
Highest on record
67.9×fiscal 2023
Lowest on record
16.0×fiscal 2024
Fiscal years on record
32023–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Krystal Biotech P/S ratio, in more detail

Today's figure is 21.1% above the fiscal 2025 year-end.

Across the 3 fiscal year-ends on record (2023–2025), the highest was 67.9× in fiscal 2023 and the lowest 16.0× in fiscal 2024. Today's P/S ratio is higher than at 67% of the 3 fiscal year-ends on record; their median is 19.0×.

History · 3 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Krystal Biotech P/S ratio, year by year

Krystal Biotech (KRYS) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today23.0×—$298.55—
202519.0× 18.3% up$246.54$12.99
202416.0× 76.4% down$156.66$9.77
202367.9×—$124.06$1.83
2022——$79.22—
2021——$69.95—
2020——$60.00—
2019——$55.38—
2018——$20.78—
2017——$10.52—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Krystal Biotech and comparable companies
CompanyP/S ratio
Twist Bioscience TWST16.2×
Protagonist Therapeutics PTGX176.8×
Krystal Biotech KRYS22.7×
10x Genomics TXG11.5×
HealthEquity HQY6.4×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on KRYS

Krystal Biotech, figure by figure

Krystal Biotech (KRYS) overview: price, valuation and scorecardAll health care companies by market value

Krystal Biotech P/S ratio: questions and answers

What is Krystal Biotech's P/S ratio?

Krystal Biotech (KRYS) trades at 23.0× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 19.0×. That is 18.3% higher than the 16.0× of fiscal 2024.

Is Krystal Biotech's P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 67% of the 3 fiscal year-ends on record; their median is 19.0×.

What are the highest and lowest P/S ratio figures on record for Krystal Biotech?

Across the 3 fiscal year-ends on record (2023–2025), the highest was 67.9× in fiscal 2023 and the lowest 16.0× in fiscal 2024.

How is Krystal Biotech's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Krystal Biotech it is on record here for 3 fiscal years, 2023 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Krystal Biotech (KRYS) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/KRYS/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.